Drug Trial Radar · NCT03915184
Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)
Last checked: Nov 19, 2026Latest source record: Dec 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
105
Planned (sponsor's estimate)
Start
Sep 25, 2019
Primary completion
Dec 31, 2024
Study completion Dec 31, 2034
Sponsor
- Lead sponsor
- CARsgen Therapeutics Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 16, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase 1b/2, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple myeloma.
Conditions
- Multiple Myeloma
Interventions
zevor-celBiological
A single autologous chimeric antigen receptor-B-cell maturation antigen (CAR-BCMA T cell) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment Related adverse events (AEs)Time frame: Day 1 - Month 60
- Identification of Maximum Tolerated Dose (MTD)Time frame: Day 1 - Month 60
- Objective response rateTime frame: Day 1 - Month 60
Locations
13 sites in 2 countries. Site status is shown where the registry gives one.
Mayo Clinic Hospital
Phoenix, Arizona
UCSF
San Francisco, California
Colorado Blood Cancer Institute
Denver, Colorado
Moffitt Cancer Center
Tampa, Florida
Dana Farber Cancer Center
Boston, Massachusetts
Mayo
Rochester, Minnesota
TriStar CMC
Nashville, Tennessee
UT Southwestern Medical Center
Dallas, Texas
MD Anderson
Houston, Texas
Methodist Hosptial
Houston, Texas
Huntsman Cancer Center
Salt Lake City, Utah
Medical College of Wisconsin
Milwaukee, Wisconsin
Princess Margaret Hospital
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.